Back to Search
Start Over
Schedule-Optimierung von Topotecan in der Therapie des Ovarialkarzinoms
- Source :
- Geburtshilfe und Frauenheilkunde. 69:384-390
- Publication Year :
- 2009
- Publisher :
- Georg Thieme Verlag KG, 2009.
-
Abstract
- Despite the increase in radical cytoreductive surgery and an initial high response rate to first-line chemotherapy with carboplatin plus paclitaxel, most women with ovarian cancer will relapse and die due to tumor progression. According to a survey performed by the NOGGO (Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie), survival represents the most important goal of treatment for patients with platinum-sensitive relapse, while in platinum-resistant relapse there is a shift to providing disease control and symptom palliation with a generally well-tolerated regimen and an emphasis on the patients' quality of life. Thus, weekly topotecan dosing instead of the standard 5-day regimen offers a promising expansion of the therapeutic spectrum. The pharmacokinetic rationale for the weekly schedule is that the inhibiting effect of topotecan on topoisomerase I is reversible after one week. The results of the randomized phase-II study of the NOGGO, which investigated the weekly schedule in comparison to the conventional 5-day schedule of topotecan, are expected for the end of this year.
- Subjects :
- Response rate (survey)
Oncology
medicine.medical_specialty
Chemotherapy
endocrine system diseases
business.industry
medicine.medical_treatment
Obstetrics and Gynecology
medicine.disease
Carboplatin
Surgery
chemistry.chemical_compound
Regimen
chemistry
Paclitaxel
Internal medicine
Maternity and Midwifery
medicine
Topotecan
Dosing
business
Ovarian cancer
medicine.drug
Subjects
Details
- ISSN :
- 14388804 and 00165751
- Volume :
- 69
- Database :
- OpenAIRE
- Journal :
- Geburtshilfe und Frauenheilkunde
- Accession number :
- edsair.doi...........5413f98f2c23a399c058765558ff15b9